Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Direct cardiovascular impact of SGLT2 inhibitors: mechanisms and effects
Abdullah Kaplan, Emna Abidi, Ahmed F. El‐Yazbi, et al.
Heart Failure Reviews (2018) Vol. 23, Iss. 3, pp. 419-437
Closed Access | Times Cited: 97

Showing 1-25 of 97 citing articles:

Heart Failure in Type 2 Diabetes Mellitus
Helena Kenny, E. Dale Abel
Circulation Research (2019) Vol. 124, Iss. 1, pp. 121-141
Open Access | Times Cited: 542
SGLT2 Inhibitors: A Review of Their Antidiabetic and Cardioprotective Effects
Anastasios Tentolouris, Panayotis K. Vlachakis, Evangelia Tzeravini, et al.
International Journal of Environmental Research and Public Health (2019) Vol. 16, Iss. 16, pp. 2965-2965
Open Access | Times Cited: 243
Diabetic Cardiomyopathy: Current and Future Therapies. Beyond Glycemic Control
Giulia Borghetti, Dirk von Lewinski, Deborah Eaton, et al.
Frontiers in Physiology (2018) Vol. 9
Open Access | Times Cited: 196
Direct cardiac effects of SGLT2 inhibitors
Sha Chen, Ruben Coronel, Markus W. Hollmann, et al.
Cardiovascular Diabetology (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 107
SGLT2 inhibition with empagliflozin improves coronary microvascular function and cardiac contractility in prediabetic ob/ob−/− mice
Damilola D. Adingupu, Sven Göpel, Julia Grönros, et al.
Cardiovascular Diabetology (2019) Vol. 18, Iss. 1
Open Access | Times Cited: 142
Empagliflozin reduces the levels of CD36 and cardiotoxic lipids while improving autophagy in the hearts of Zucker diabetic fatty rats
Alana Aragón‐Herrera, Sandra Feijóo‐Bandín, Manuel Otero Santiago, et al.
Biochemical Pharmacology (2019) Vol. 170, pp. 113677-113677
Closed Access | Times Cited: 140
Class effects of SGLT2 inhibitors on cardiorenal outcomes
Aaron Y. Kluger, Kristen M. Tecson, Andy Lee, et al.
Cardiovascular Diabetology (2019) Vol. 18, Iss. 1
Open Access | Times Cited: 135
Sodium–glucose cotransporter 2 inhibitors and inflammation in chronic kidney disease: Possible molecular pathways
Habib Yaribeygi, Alexandra E. Butler, Stephen L. Atkin, et al.
Journal of Cellular Physiology (2018) Vol. 234, Iss. 1, pp. 223-230
Open Access | Times Cited: 129
Cardiovascular outcomes in trials of new antidiabetic drug classes: a network meta-analysis
Yue Fei, Man-Fung Tsoi, Bernard Man Yung Cheung
Cardiovascular Diabetology (2019) Vol. 18, Iss. 1
Open Access | Times Cited: 129
Off-target effects of sodium-glucose co-transporter 2 blockers: empagliflozin does not inhibit Na+/H+ exchanger-1 or lower [Na+]i in the heart
Yu Jin Chung, Kyung Chan Park, Sergiy Tokar, et al.
Cardiovascular Research (2020) Vol. 117, Iss. 14, pp. 2794-2806
Open Access | Times Cited: 116
Amelioration of diastolic dysfunction by dapagliflozin in a non-diabetic model involves coronary endothelium
Donato Cappetta, Antonella De Angelis, Loreta Pia Ciuffreda, et al.
Pharmacological Research (2020) Vol. 157, pp. 104781-104781
Closed Access | Times Cited: 106
Cardiomyopathy Associated with Diabetes: The Central Role of the Cardiomyocyte
Tiziana Filardi, Barbara Ghinassi, Angela Di Baldassarre, et al.
International Journal of Molecular Sciences (2019) Vol. 20, Iss. 13, pp. 3299-3299
Open Access | Times Cited: 83
Inflammatory Mechanisms of Diabetes and Its Vascular Complications
Lyudmila Viktorovna Nedosugova, Yuliya V. Markina, Л. А. Бочкарева, et al.
Biomedicines (2022) Vol. 10, Iss. 5, pp. 1168-1168
Open Access | Times Cited: 48
SGLT2 inhibition attenuates arterial dysfunction and decreases vascular F-actin content and expression of proteins associated with oxidative stress in aged mice
Rogério N. Soares, Francisco I. Ramirez‐Perez, Francisco J. Cabral-Amador, et al.
GeroScience (2022) Vol. 44, Iss. 3, pp. 1657-1675
Open Access | Times Cited: 41
Mechanisms of benefits of sodium-glucose cotransporter 2 inhibitors in heart failure with preserved ejection fraction
Arjun Pandey, Deepak L. Bhatt, Avinash Pandey, et al.
European Heart Journal (2023) Vol. 44, Iss. 37, pp. 3640-3651
Closed Access | Times Cited: 35
Dapagliflozin Attenuates Cardiac Remodeling in Mice Model of Cardiac Pressure Overload
Lin Shi, Diqi Zhu, Shoubao Wang, et al.
American Journal of Hypertension (2019) Vol. 32, Iss. 5, pp. 452-459
Open Access | Times Cited: 69
Molecular Insights Into SARS COV-2 Interaction With Cardiovascular Disease: Role of RAAS and MAPK Signaling
Zena Wehbe, Safaa H. Hammoud, Nadia Soudani, et al.
Frontiers in Pharmacology (2020) Vol. 11
Open Access | Times Cited: 56
Molecular Mechanisms Responsible for Diastolic Dysfunction in Diabetes Mellitus Patients
Jovana Nikolajević Starčević, Miodrag Janić, Mišo Šabovič
International Journal of Molecular Sciences (2019) Vol. 20, Iss. 5, pp. 1197-1197
Open Access | Times Cited: 51
<p>SGLT2 Inhibitors: A Novel Player in the Treatment and Prevention of Diabetic Cardiomyopathy</p>
Na Li, Hong Zhou
Drug Design Development and Therapy (2020) Vol. Volume 14, pp. 4775-4788
Open Access | Times Cited: 46
Cardiovascular Outcome in Patients Treated With SGLT2 Inhibitors for Heart Failure: A Meta-Analysis
Gloria M. Gager, Georg Gelbenegger, Bernd Jilma, et al.
Frontiers in Cardiovascular Medicine (2021) Vol. 8
Open Access | Times Cited: 36
Metformin, pioglitazone, dapagliflozin and their combinations ameliorate manifestations associated with NAFLD in rats via anti-inflammatory, anti-fibrotic, anti-oxidant and anti-apoptotic mechanisms
Hager H. Shaaban, Ibrahim AlZaim, Ahmed El‐Mallah, et al.
Life Sciences (2022) Vol. 308, pp. 120956-120956
Closed Access | Times Cited: 27
Effects of sodium-glucose co-transporter-2 inhibitors on kidney, cardiovascular, and safety outcomes in patients with advanced chronic kidney disease: a systematic review and meta-analysis of randomized controlled trials
Haiyan Cao, Xiaosheng Rao, Junya Jia, et al.
Acta Diabetologica (2022) Vol. 60, Iss. 3, pp. 325-335
Closed Access | Times Cited: 25
Characterization of the SGLT2 Interaction Network and Its Regulation by SGLT2 Inhibitors: A Bioinformatic Analysis
Zofia Wicik, A Nowak, Joanna Jarosz-Popek, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 23
Resting heart rate and cardiovascular outcomes in diabetic and non-diabetic individuals at high cardiovascular risk analysis from the ONTARGET/TRANSCEND trials
Michael Böhm, Helmut Schumacher, Koon Teo, et al.
European Heart Journal (2018) Vol. 41, Iss. 2, pp. 231-238
Closed Access | Times Cited: 43
Effects of sodium‐glucose cotransporter‐2 inhibitors on the cardiovascular and renal complications of type 2 diabetes
Robert Ćhilton
Diabetes Obesity and Metabolism (2019) Vol. 22, Iss. 1, pp. 16-29
Closed Access | Times Cited: 41
Page 1 - Next Page

Scroll to top